Medicus Pharma Ltd. has entered into a new engagement with Deloitte LLP, appointing the firm as the exclusive lead financial adviser. The collaboration aims to identify one or more partners for an out-licensing transaction involving Doxorubicin Microneedle Array (D-MNA), a treatment for Basal Cell Carcinoma in adults. This agreement allows for flexibility in the transaction structure, which may include licensing or other mechanisms. Medicus Pharma Ltd. will compensate Deloitte with a retainer and a contingent success fee upon the successful completion of a transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-25-013266), on July 30, 2025, and is solely responsible for the information contained therein.